Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Allergy Bestselling Drug: Kyowa Yakuhin’s New North Pole Sinus Infection Capsule W

This article was originally published in PharmAsia News

Executive Summary

Kyowa Yakuhin's North Pole Sinus Infection Capsual W was identified as the top selling antihistamine drug, accounting for 60 percent of the oral allergy drug market, according to Shinjuku drug store chain Matsumoto Kyoshi. Second in sales was Sato Pharma's Sutonarini S. The convenience of taking the drug once or twice daily, coupled with long- lasting effects, are reasons for their popularity. However, side effect of drowsiness common in antihistamines turned some people to Kyorin Pharma's Cool One Sinus Infection Soft Capsule S, which has anti-drowsiness ingredients. OTC switches such as Daiichi Sankyo's AG series and Zaditen by Norvatis are also drawing attention. (Click for more-Japanese language

You may also be interested in...

Trump Most-Favored-Nation Pricing Rule Criticized By The AAM

Mooted some time ago, the Medicare Part D Drug Rebate Rule and the Medicare Part B Most-Favored-Nation Model have now been finalized by US President Donald Trump. But US off-patent body the Association for Accessible Medicines feels “further action is necessary.”

Lannett Plans Seven Launches In Fiscal Year 2021

Lannett will launch a further seven products in fiscal 2021, after launching four products recently in the first quarter of FY21. The company also plans to pay off its Term Loan ‘A’ in full, by the end of November 2020. 

Pfizer Picks Up EU Pegfilgrastim Approval

Pfizer has now received a formal European Commission approval for its Nyvepria biosimilar pegfilgrastim. The approval puts the firm in direct competition with several other versions of the Neulasta original.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts